Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data

Health Economics

Volumn 8, Issue 3, 1999, Pages 203-211

  Willan, Andrew R ^a   O'brien, Bernie J ^b  

^a ST JOSEPH S HOSPITAL   (Canada)

^b NONE

Author keywords

Confidence intervals; Cost effectiveness; ICER; Power; Sample size

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE; STATISTICS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG EVALUATION; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; MALE; MODELS, ECONOMETRIC; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SAMPLE SIZE;

EID: 0032892898     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1050(199905)8:3<203::AID-HEC413>3.0.CO;2-7     Document Type: Article

References (33)

1. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. Woden (ACT) Department of Health, Housing and Community Services, 1990.
2. Detsky, A.S. A guideline for preparation of economic analysis of pharamacetical products: a draft document for Ontario and Canada. Pharmacoeconomics 1993; 3: 354-361.
3. Leaf, A. Cost effectiveness as a criterion for Medicare coverage. New England Journal of Medicine 1989; 321: 898-900.
4. O'Brien, B.J. Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Medical Care 1996; 34(12): DS99-DS108.
5. Weinstein, M.C., Fineberg, H.V., Elstein, A.S., Fraser, H.S., Neuhauser, D., Neutra, R.R. and McNeil, B.J. Clinical decision analysis. Philadelphia: W.B. Saunders Company, 1980.
6. Briggs, A.H., Sculpher, M.J. and Buxton, M.J. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Economics 1994; 3: 95-104.
7. Mark, D.B,. Hlarky, M.A., Califf, R.M. et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New England Journal of Medicine 1995; 332: 1418-1424.
8. Oster, G., Borok, G.M., Menzin, J. et al. Cholesterol-reduction intervention study (CRIS). Archives of Internal Medicine 1996; 156: 731-739.
9. Schulman, K.A., Buxton, M., Glick, H. et al. Results of the economic evaluation of the FIRST suty. International Journal in Technology Assessment in Health Care 1996; 12: 698-713.
10. O'Brien, B.J., Drummond, M.F., Labelle, R.J. and Willan, A.R. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in heath care. Medical Care 1994; 32: 150-163.
11. Willan, A.R. and O'Brien, B.J. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Economics 1996; 5: 297-305.
12. Chaudhary, M.A. and Stearns, S.C. Confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Statistics in Medicine 1996; 15: 1447-1458.
13. Mullahy, J. and Manning, W. Statistical issues of cost-effectiveness analysis. In: Sloan, F. (ed.) Valuing health care. Cambridge: Cambridge University Press, 1994: 149-184.
14. Mullahy, J. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. Medical Care 1996; 34(12 Suppl): DS124-DS135.
15. Manning, W.G., Fryback, D.G. and Weinstein, M.C. Reflecting uncertainty in cost effectiveness analysis. In: Gold, M.R., Siegel, J.E., Russell, L.B. and Weinstein, M.C. (eds.) Cost effectiveness in health and medicine. New York: Oxford University Press, 1996.
16. Briggs, A.M., Wonderling, D.E. and Mooney, C.Z. Pulling cost-effectiveness analysis up by its bootstraps; a non-parametric approach to confidence interval estimation. Health Economics 1997; 6: 327-340.
17. van Hout, B.A., Al, M.J., Gordon, G.S. and Rutten, F.F.H. Costs, effects and C/E ratios alongside a clinical trial. Health Economics 1994; 3: 309-319.
18. Wakker, P. and Klaassen, M.P. Confidence intervals for cost/effectiveness ratios. Health Economics 1995; 4: 373-381.
19. Polsky, D., Glick, H.A., Willke, R. and Schulman, K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Economics 1997; 6: 243-252.
20. Drummond, M.F., O'Brien, B.J., Stoddart, G.L. and Torrance, G.W. Methods for the economic evaluation of health care programmes, 2nd edition. Oxford: Oxford University Press, 1997.
21. Stinnett, A.A. and Mallahy, J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998; 18(Suppl.): S57-S67.
22. Briggs, A.H. and Gray, A.M. Power and sample size calculations for stochastic cost-effectiveness analysis. Medical Decision Making 1998; 18(Suppl.): S81-S92.
23. Drummond, M.F., Richardson, W.S., O'Brien, B.J., Levine, M. and Heyland, D. for the Evidence-based Medicine Working Group. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. Part A: are the results of the study valid? Journal of the American Medical Association 1997; 277: 1552-1557.
24. O'Brien, B.J., Heyland, D., Richardson, W.S., Levine, M. and Drummond, M.F. for the Evidence-based Medicine Working Group. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. Part B: What are the results and will they help me in caring for my patients? Journal of the American Medical Association 1997; 277: 1802-1806.
25. Tannock, I.F., Osoba, D., Stockler, M.R. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian trial with palliative endpoints. Journal of Clinical Oncology 1996; 14: 1756-1764.
26. Siegel, J.E., Weinstein, M.C., Russell, L.B. and Gold, M.R. for the Panel on Cost-effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness. Journal of the American Medical Association 1996; 276: 1339-1341.
27. Sacristan, J.A. and Obenchain, R.L. Reporting cost-effectiveness analysis with confidence. Journal of the American Medical Association 1997; 277: 375.
28. Stinnett, A.A. and Mallahy, J. The negative side of cost-effectiveness analysis. Journal of the American Medical Association 1997; 277: 1931-1932.
29. Doubilet, P., Weinstein, M.C. and McNeil, B.J. Use and misuse of the term 'cost-effective' in medicine. New England Journal of Medicine 1986; 314: 253-255.
30. Laupacis, A., Feeny, D., Detsky, A. and Tugwell, P. How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 1992; 146: 473-481.
31. Willan, A.R. Power function arguments in support of an alternative approach for analyzing management trials. Controlled Clinical Trials 1994; 15: 211-219.
32. O'Brien, B.J. and Gafni, A. When do the 'dollars' make sense? Toward a conceptual framework for contingent valuation studies in health care. Medical Decision Making 1996; 16: 288-299.
33. Diener, A., O'Brien, B.J. and Gafni, A. Health care contingent valuation studies: a review and classification of the literature. Health Economics 1998; 7: 313-326.